Stowaways in the cargo: Contaminating nucleic acids in rAAV preparations for gene therapy

Abstract excerpt

Recombinant AAV (rAAV) is the most used delivery vector for clinical gene therapy. However, many issues must be addressed before safer and more widespread implementation can be achieved. At present, efficacies are highly variable across trials and patients, and immune responses after treatment are widely reported. Although rAAV is capable of directly delivering gene-encoded therapeutic sequences, increased...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to CRISPR and Genetic Engineering
• Share to Viral gastroenteritis research and epidemiology
• Share to Virus-based gene therapy research